Zacks small cap research.

Zacks Small-Cap Research Lisa Thompson 312-265-9154 [email protected] scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 September 1, 2021 Raising …About Zacks Small-Cap Research Zacks/SCR prepares company-sponsored, independent research and related content for distribution through a multitude of investor and media channels, both traditional ...Zacks Investment Research Page 4 scr.zacks.com The company has already presold the bulk of its 2023 capacity (and likely a significant portion of 2024 capacity) to customers and continues to announce customer wins with industry leaders in the energy storage market.OTC:NEXCF. READ THE FULL NEXCF RESEARCH REPORT. Nextech AR’s (OTC:NEXCF) Q3 report showed a rapid uptake of its AR 3D model subscription business which grew 192% sequentially. It plans to deliver $700,000 worth of models to Amazon (we believe) alone in Q4 and the business continues to thrive. Just as …

Nov 15, 2023 · SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the ... Zacks Small-Cap Research Sponsored – Impartial – Comprehensive October 9, 2023 John D. Vandermosten, CFA 312-265-9588 / [email protected] scr.zacks.com 10 S. …Zacks Small Cap Research. PLX: Back of the Envelope. Read full article. 1. Zacks Small Cap Research. May 30, 2023 at 8:00 AM ...

Zacks Small-Cap Research Sponsored – Impartial – Comprehensive October 9, 2023 John D. Vandermosten, CFA 312-265-9588 / [email protected] scr.zacks.com 10 S. …ORMP: Data from NASH Phase 2 Study – Positive Takeaways . 11/21/2022. Download (opens in new window)

Wheel center caps are an important component of your vehicle’s overall aesthetic appeal. Not only do they enhance the appearance of your wheels, but they also protect the hub and lug nuts from dirt, debris, and damage.SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …Jan 5, 2023 · By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Third Quarter Financial and Operational Review Tenax Therapeutics, Inc. (NASDAQ:TENX) reported 3Q:23 results on November 13, 2023 via its filing of Form 10-Q with the SEC. Since the filing of the second quarter 10-Q in mid-August, the company has finished compiling and submitting its investigational new drug (IND) By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update HyBryte™ Expanded Treatment Trial Underway On August 10, 2023, Soligenix, Inc. (NASDAQ:SNGX) announced the start of the investigator-initiated study that is designed to examine the expanded treatment, including up to 12 months of treatment, with HyBryte in patients with early-stage cutaneous T cell lymphoma ...Zacks Small-Cap Research Lisa Thompson 312-265-9154 [email protected] scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 July 22, 2021 PKKFF: Peak Fintech Expects to Grow 145% this Year and Be Profitable Compared to its peers in the fintech space who trade at an average of 12.3 times

Zacks Rank N/A BIOR: Precision Release – Surgical Strike on the GI Tract Zacks Small-Cap Research Joh Sponsored – Impartial – Comprehensive scr.zacks.com 10 S. …

By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Phase 2b Data for EB01 in January 2023 Edesa Biotech, Inc. (NASDAQ:EDSA) is currently conducting a double blind, placebo controlled trial to evaluate the safety and efficacy of 2.0% EB01 cream in approximately 170 evaluable subjects in …

Expense Ratio 1.390%. Distribution Fee Level High. Share Class Type No Load. Category Small Blend. Investment Style Small Blend. Min. Initial Investment 2,500. Status Open. TTM Yield 0.47% ...David Bautz, PhD, Senior Analyst for Zacks Small-Cap Research, with 9 years of direct experience in the securities and investment industry. David’s research articles have been posted extensively on Yahoo Finance News and throughout life sciences social media circles. Prior to joining Zacks in 2014, David was an NRSA postdoctoral fellow ...By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update AdCom Granted for NurOwn® On March 27, 2023, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) announced that the U.S. Food and Drug Administration (FDA) has granted an Advisory Committee (AdCom) meeting to discuss …$31.77 USD -0.10 (-0.31%) Zacks MF Rank NA View All Zacks Mutual Fund Rank #1's Zacks Mutual Funds Categories » Small Cap Blend Latest Performance as of Oct 31, 2023 * Annual for three...Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research. BETHESDA, Md., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Gain …

Zacks Rank N/A INBS: Australia Off to a Strong Start Zacks Small-Cap Research John D. Vandermosten, CFA Sponsored – Impartial – Comprehensive scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 September 5, 2023 312-265-9588 / [email protected] ESTIMATES Revenue ns of USD) Q1 Q2 Q3 Q4 Year SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.Apr 10, 2023 · RVLP: Bright-Eyed and Bushy-Tailed. 04/10/2023. By John Vandermosten, CFA. NASDAQ:RVLP. The Journal of Plastic, Reconstructive and Aesthetic Surgery published an article entitled The Effect of Topical Oxymetazoline on Eyelid Position, Eye Redness, and Patient-Reported Eye Appearance: A Randomized Controlled Trial. CXW intends to redeem the $153.9 million outstanding of its 4.625% senior notes that mature in 2023 in full on February 1, 2023, using a combination of cash on hand and existing capacity under its revolving credit facility. CXW had $185.3 million of cash at the end of 3Q22 and its $250.0 million revolver was undrawn.By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update First Patient Dosed in Phase 1b/2 Trial for Exebacase in Chronic Knee Prosthetic Joint Infections On April 26, 2023, ContraFect Corp. (NASDAQ:CFRX) announced the first patient has been dosed in the Phase 1b/2 clinical trial of exebacase in the setting of a minimally-invasive arthroscopic debridement, antibiotics,Thomas Kerr, CFA is a Senior Equity Research Analyst with Zacks Small-Cap Research, with over 25 years of securities industry experience in Technology, Consumer, Industrials, Med-Tech, Healthcare & Biotechnology sectors. Prior to joining Zacks in 2021, Tom was Senior Investment Specialist at WestPac Wealth Partners, Chief Investment Officer ...

On February 6, 2023, Arrowhead announced financial results for the first quarter of fiscal year 2023 that ended December 31, 2022. The company reported revenue of approximately $62.5 million for the first quarter of fiscal year 2023 compared to approximately $27.4 million for the first quarter of fiscal year 2022.By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Phase 2b Data for EB01 in January 2023 Edesa Biotech, Inc. (NASDAQ:EDSA) is currently conducting a double blind, placebo controlled trial to evaluate the safety and efficacy of 2.0% EB01 cream in approximately 170 evaluable subjects in …

Zacks Small-Cap Research Sponsored – Impartial – Comprehensive November 8, 2023 John D. Vandermosten, CFA scr.zacks.com 312-265-9588 / [email protected] …Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE. 1. Reviva RECOVER Topline Results Data Presentation, October 30, 2023.SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, ...Nov 27, 2023 · 06/12/2023. UHAL: U-Haul Holding Company Reports Financial Results for Fiscal 2023; Demand for truck rentals slowed in the second half of FY2023. Management aspires to hold the market share gains and has expectations that the self-moving market will stabilize in FY2024. 06/08/2023. SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …“Yes! Success!” “Yes! Success!” It wasn’t quite “Mr. Watson. Come Here. I need you.” but it could prove to be just as revolutionary: Researchers at the University of Washington have completed the first experiment demonstrating human brain-t...Net R&D expenses for the third quarter of 2023 were $3.3 million, compared to $3.8 million during the third quarter of 2022. The decrease was primarily due to decreased costs related to the Phase 3 clinical trial and decreased payroll expense, travel, materials, depreciation, and other activities. G&A expenses for the third quarter of 2023 were ...By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Phase 2b Data for EB01 in January 2023 Edesa Biotech, Inc. (NASDAQ:EDSA) is currently conducting a double blind, placebo controlled trial to evaluate the safety and efficacy of 2.0% EB01 cream in approximately 170 evaluable subjects in …Zacks Rank N/A FY21 Results; IO Revenues Analysis Zacks Small-Cap Research John D. Vandermosten, CFA Sponsored – Impartial – Comprehensive scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 January 11, 2022 312-265-9588 / [email protected] Revenue Q1 Q2 Q3 Q4 Year (Dec) (Mar) (Jun) (Sep) (Sep)

Apr 10, 2023 · RVLP: Bright-Eyed and Bushy-Tailed. 04/10/2023. By John Vandermosten, CFA. NASDAQ:RVLP. The Journal of Plastic, Reconstructive and Aesthetic Surgery published an article entitled The Effect of Topical Oxymetazoline on Eyelid Position, Eye Redness, and Patient-Reported Eye Appearance: A Randomized Controlled Trial.

Zacks Rank N/A FRESH Results in November Zacks Small-Cap Research John D. Vandermosten, CFA Sponsored – Impartial – Comprehensive scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 September 6, 2022 312-265-9588 / [email protected] Our valuation uses a DCF model and a 15% discount rate. It

A conference call with investors and analysts was held immediately following the release. 2Q:23 revenues of $3.6 million were ahead of our initial estimates and matched revised company guidance. Net loss per share was ($1.03). Management reiterated its outlook of revenues between $14.0 and $15.0 million in 2023.Nov 15, 2023 · SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the ... Put on Your Rally Cap, as We Turn the Last Two Inside-Out Do you get the sense that folks were more bullish after last Wednesday's rally than they were after Monday's rally? That's the sense I get. I suppose that is because last week's rug ...Nov 15, 2023 · SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the ... By Lisa Thompson OTC:NEXCF CSE:TGGL READ THE FULL NEXCF RESEARCH REPORT Nextech (OTC:NEXCF) reported Q2 revenues of $1.4 million, up $100,000 sequentially from Q1 and 153% from Q2 2022. The company had preannounced this number on August 1st. Investors are still awaiting news that Nextech’s 3D modeling …The following disclosures relate to relationships between Zacks Small-Cap Research ( Zacks SCR ), a division of Zacks Investment Research ( ZIR ), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe. ANALYST DISCLOSURES. Zacks SCR Analysts hereby certify that the view expressed in this research report or article ...May 4, 2023 · First Quarter 2023 Financial and Operational Results. For the quarter ending March 31, 2023, electroCore Inc. (NASDAQ:ECOR) posted revenues of approximately $2.8 million vs. $1.9 million in the prior year quarter. This represents growth of nearly 50%, driven by increases in the VA/DOD segment and commercial revenues augmented by electroCore’s ... By John Vandermosten, CFA NASDAQ:MDXG READ THE FULL MDXG RESEARCH REPORT First Quarter 2023 Results MiMedx Group, Inc. (NASDAQ:MDXG) reported first quarter 2023 revenues of $71.7 million, representing a 22% year over year growth rate, surpassing our $64.2 million estimate. Loss from operations was ($3.4) million, …Zacks Equity Research November 23, 2023. CVX Quick Quote CVX ... Overall, they are usually a stable option, with less risk and more sure-fire cash flows than …By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Third Quarter Financial and Operational Review Tenax Therapeutics, Inc. (NASDAQ:TENX) reported 3Q:23 results on November 13, 2023 via its filing of Form 10-Q with the SEC. Since the filing of the second quarter 10-Q in mid-August, the company has finished compiling and submitting its investigational new drug (IND)

Brian Lantier, CFA is a Senior Research Analyst with Zacks Small-Cap Research covering technology, software, consumer internet and special situations. Brian has over 20 years of equity research experience. Brian began his career as a member of the small cap growth team at Lehman Brothers where his coverage universe included software, satellites ...INX (OTC:INXDF) announced that Republic Group, described as “a global financial firm operating a digital merchant bank and a network of investment platforms,” is investing $5.25 million into the company in exchange for approximately 9.5% of outstanding shares. The deal, according to INX, values INX at approximately $50 million before the ...SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …May 4, 2023 · First Quarter 2023 Financial and Operational Results. For the quarter ending March 31, 2023, electroCore Inc. (NASDAQ:ECOR) posted revenues of approximately $2.8 million vs. $1.9 million in the prior year quarter. This represents growth of nearly 50%, driven by increases in the VA/DOD segment and commercial revenues augmented by electroCore’s ... Instagram:https://instagram. best offshore brokers without pdt rulepolaris car electriccustomers bank news2024 social security cola estimate Thomas Kerr, CFA is a Senior Equity Research Analyst with Zacks Small-Cap Research, with over 25 years of securities industry experience in Technology, Consumer, Industrials, Med-Tech, Healthcare & Biotechnology sectors. Prior to joining Zacks in 2021, Tom was Senior Investment Specialist at WestPac Wealth Partners, Chief Investment Officer ... dollet treebest ai stock plays SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …Oct 26, 2023 · By Brad Sorensen, CFA NASDAQ:MIRA READ THE FULL MIRA RESEARCH REPORT MIRA Pharmaceuticals (NASDAQ:MIRA) is a preclinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic cannabinoid analog for the treatment of adult patients with neuropathic pain as well as anxiety and cognitive decline typically associated with early-stage dementia. Most yerba stock SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …Zacks Rank N/A INBS: Australia Off to a Strong Start Zacks Small-Cap Research John D. Vandermosten, CFA Sponsored – Impartial – Comprehensive scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 September 5, 2023 312-265-9588 / [email protected] ESTIMATES Revenue ns of USD) Q1 Q2 Q3 Q4 Year